相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- A UNIST research center has been selected for the Korean ARPA-H Project to develop external blood purification technology that filters metastasis-promoting substances from the bloodstream to block cancer spread. - The center will receive about 8 billion won ($5.8 million) over four and a half years, with Professor Kang Joo-heon serving as lead researcher. - The approach builds on a sepsis blood purification platform and will initially target colorectal cancer patients at risk of recurrence or metastasis, with plans to extend to other metastatic cancers. - A collaborative network including Yonsei University College of Medicine, Seoul National University Bundang Hospital, Artblood, Sebica, Evertry, and the Korea Testing & Research Institute will support clinical application and commercialization.
- The A-CLOSE trial found clopidogrel monotherapy was noninferior to extended DAPT for the primary net adverse clinical events endpoint (5.0% vs. 5.1%; p=0.001 for noninferiority) in high ischemic risk patients. - Extended DAPT provided greater protection against major ischemic events, including death, while clopidogrel monotherapy significantly reduced major or clinically relevant bleeding. - Key ischemic events occurred more frequently with clopidogrel monotherapy (3.7% vs. 1.6%; p<0.001), whereas BARC type 2, 3 or 5 bleeding was lower (1.8% vs. 4.1%; p<0.001). - Investigators concluded that no single strategy is best for every patient, and long-term antiplatelet therapy should be individualized through shared decision-making.
- Lunit's SCOPE IO artificial intelligence platform successfully predicted immunotherapy response in three major cancer types through analysis of routine histopathology slides presented at ESMO 2025. - In colorectal cancer trials, biomarker-high patients showed significantly improved progression-free survival and overall survival when treated with atezolizumab combinations compared to biomarker-low patients. - The AI tool demonstrated 60.5% response rates versus 23.2% for inflamed versus non-inflamed tumors in advanced clear cell renal cell carcinoma patients treated with nivolumab plus ipilimumab. - Validation studies across lung, kidney, and colorectal cancers support the platform's potential to guide personalized immunotherapy treatment selection in clinical practice.
- The phase 2 PALOMA-2 study demonstrated that subcutaneous amivantamab plus chemotherapy achieved a 76% objective response rate in patients with EGFR exon 20 insertion-mutated advanced NSCLC. - Results showed consistency with the pivotal PAPILLON study, with a clinical benefit rate of 94% and median progression-free survival of 12.2 months at 10-month follow-up. - The subcutaneous formulation offers enhanced tolerability and convenience without sacrificing efficacy compared to intravenous administration. - European Commission approval in April 2025 for subcutaneous amivantamab formulations is expected to expand clinical applicability and lead to additional regulatory approvals.
- S.BIOMEDICS announced positive 12-month results from its Phase 1/2a trial of A9-DPC cell therapy for Parkinson's disease, showing favorable safety profile with no tumorigenesis or immune reactions observed. - The study demonstrated significant motor function improvements, with MDS-UPDRS Part III scores decreasing by 12.7 points in low-dose and 15.5 points in high-dose groups compared to baseline. - Brain imaging revealed increased dopamine transporter signals that correlated with clinical improvements, providing mechanistic evidence for the therapy's effectiveness in restoring neural connectivity. - The therapy consists of high-purity dopaminergic progenitor cells derived from human embryonic stem cells, transplanted bilaterally into the putamen of 12 Parkinson's patients.
- Luveltamab tazevibulin demonstrated a 32% overall response rate in platinum-resistant ovarian cancer patients with FRα expression ≥25%, showing similar efficacy in both low-medium and high expression subgroups. - The antibody-drug conjugate achieved a remarkable 96% disease control rate when administered at 5.2 mg/kg with G-CSF prophylaxis for the first two cycles, then 4.3 mg/kg in subsequent cycles. - Common side effects included arthralgia, nausea, and neutropenia, with researchers selecting the optimized dose regimen for the ongoing phase 3 portion of the REFRΑME-O1 trial.
• Phase 2 NIVEC trial demonstrates 80% clinical complete response rate with nivolumab in patients with resectable dMMR/MSI-H endometrial cancer, allowing many to avoid surgery. • No disease recurrence was observed during follow-up, and the treatment showed a manageable safety profile with only two grade 3/4 adverse events reported. • The trial has now entered its second stage, recruiting an additional 15 patients after successfully demonstrating efficacy in stage 1 of the study.
- A new study from Yonsei University demonstrates that enhanced monofocal intraocular lenses (IOLs) are as effective as standard IOLs in treating glaucoma patients while potentially offering improved intermediate vision. - Research involving 296 eyes showed significant post-operative improvements in visual acuity, intraocular pressure, and retinal nerve fiber layer thickness across both enhanced and standard IOL groups. - The study validates enhanced monofocal IOLs as a viable treatment option for glaucoma patients of all severity levels, with comparable safety and efficacy to standard monofocal lenses.
